## **Mahesh Patel**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4850914/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<p>Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence</p> . Drug Design, Development and Therapy, 2019, Volume 13, 4351-4365.	4.3	44
2	Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. Journal of Antimicrobial Chemotherapy, 2005, 56, 1130-1133.	3.0	20
3	In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. Journal of Medical Microbiology, 2019, 68, 1129-1136.	1.8	15
4	WCK 4873 (Nafithromycin): Assessment of In Vitro Human CYP Inhibitory Potential of a Novel Lactone-Ketolide. Open Forum Infectious Diseases, 2016, 3, .	0.9	8
5	Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. Bioorganic and Medicinal Chemistry Letters, 2021, 54, 128432.	2.2	8
6	<i>In Vivo</i> Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
7	Assessment of the <i>in vitro</i> cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. Xenobiotica, 2021, 51, 251-261.	1.1	5
8	Assessment of <i>inÂvitro</i> inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica, 2020, 50, 1149-1157.	1.1	4
9	Preclinical safety evaluation of levonadifloxacin, a novel antiâ€methicillinâ€resistant <i>Staphyloccocus aureus</i> benzoquinolizine fluoroquinolone by intravenous and oral administration. Journal of Applied Toxicology, 2022, 42, 1354-1370.	2.8	2